Detalhe da pesquisa
1.
Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management.
Eur J Nucl Med Mol Imaging
; 48(12): 4016-4027, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33903926
2.
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.
Eur J Nucl Med Mol Imaging
; 48(4): 1200-1210, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970216
3.
18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD).
BMC Cancer
; 21(1): 1015, 2021 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34507549
4.
Pain in survivors of Ewing sarcoma: Prevalence, associated factors and prediction of recurrence.
Pediatr Blood Cancer
; 68(3): e28801, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33179838
5.
Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis.
Eur J Nucl Med Mol Imaging
; 47(9): 2106-2112, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32062682
6.
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Hematol Oncol
; 38(3): 244-256, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32067259
7.
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Ann Hematol
; 98(4): 897-907, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30610279
8.
Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients.
J Neurooncol
; 141(1): 83-94, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30506500
9.
FDG-PET proves to be reliable in the diagnostic workup of a rare cardiac hemangioma.
J Card Surg
; 34(10): 1097-1099, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31374577
10.
18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.
Eur J Nucl Med Mol Imaging
; 45(8): 1329-1334, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29541812
11.
Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer.
Eur J Nucl Med Mol Imaging
; 45(12): 2055-2061, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30027419
12.
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.
Eur J Nucl Med Mol Imaging
; 45(5): 860-877, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29335762
13.
Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?
Pediatr Blood Cancer
; 65(7): e27011, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29480574
14.
Multimodal Imaging of Patients With Gliomas Confirms 11C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy.
Mol Imaging
; 16: 1536012116687651, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28654379
15.
Metabolic volume performs better than SUVmax in the detection of left ventricular assist device driveline infection.
Eur J Nucl Med Mol Imaging
; 44(11): 1870-1877, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28547176
16.
[(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer.
Eur J Nucl Med Mol Imaging
; 43(2): 212-220, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26419851
17.
[(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Eur J Nucl Med Mol Imaging
; 43(10): 1765-72, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27059853
18.
Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.
Eur J Nucl Med Mol Imaging
; 45(6): 1076-1077, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29445927
19.
Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [18F]F-PSMA 1007 PET.
Cancers (Basel)
; 14(20)2022 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291925
20.
Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging.
Ann Nucl Med
; 36(3): 293-301, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34854061